Complement in antibody therapy: Friend or foe?

Blood

Volumn 114, Issue 26, 2009, Pages 5247-5248

  Introna, Martino ^a   Golay, Josée ^a  

^a Ospedali Riuniti di Bergamo   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; COMPLEMENT MEMBRANE ATTACK COMPLEX; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; RITUXIMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LYMPHOMA; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 77950389177     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-10-249532     Document Type: Note

References (8)

1. Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complementmediated cell lysis. Blood. 2000;95(12):3900-3908.
2. Lim SH, Beers SA, French RR, Johnson PW, Glennie MJ, Cragg MS. Anti-CD20 monoclonal antibodies- historical and future perspectives [published online ahead of print September 22, 2009]. Haematologica. doi:10.3324/haematol.2008. 001628.
3. Wang S-Y, Veeramani S, Racila E, et al. Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate humanNKcells and improves the efficacy of monoclonal antibody therapy in an in vivo model. Blood. 2009;114(26):5322-5330.
4. Wang SY, Racila E, Taylor RP, Weiner GJ. NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Blood. 2008;111(3):1456-1463.
5. Beers SA, Chan CH, James S, et al. Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood. 2008;112(10):4170-4177.
6. Hamaguchi Y, Uchida J, Cain DW, et al. The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. J Immunol. 2005;174(7):4389-4399.
7. Racila E, Link BK, Weng WK, et al. A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin Cancer Res. 2008;14(20):6697-6703.
8. Klepfish A, Gilles L, Ioannis K, Eliezer R, Ami S. Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement/rituximab interactions & clinical results in refractory CLL. Ann N YAcad Sci. 2009;1173:865-873.